- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07038148
- Original Trial
Single-Stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy
Exploring the Efficacy of Single Stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy, More Leak?
Some patients who have had a gastric bypass (Roux-en-Y gastric bypass or one anastomosis gastric bypass) develop long-term problems such as nutritional deficiencies, intractable dumping syndrome, retrograde intussusception or weight regain, and some cannot afford the lifelong vitamin supplements the bypass requires. When these problems do not respond to non-surgical treatment, the bypass can be reversed to normal anatomy, but many patients refuse reversal because they fear regaining weight. Converting the bypass to a sleeve gastrectomy is an alternative that restores food passage through the duodenum while keeping a restrictive operation.
This single-arm study evaluates the efficacy, safety and patient outcomes of single-stage laparoscopic stapled conversion of gastric bypass to sleeve gastrectomy in adults at Kasr Al-Ainy hospitals, Cairo University. Patients are followed for 6 months after surgery for nutritional status, weight regain, quality of life, reflux (GERD) symptoms and postoperative complications, including leak.
Study Overview
Status
Intervention / Treatment
Detailed Description
Background: Laparoscopic gastric bypass, including Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB), is one of the most frequently performed metabolic bariatric procedures. As the number of bypass operations increases, complications are reported more often. Most can be managed non-surgically, but a small number of persistent cases require reversal to normal anatomy or conversion to another procedure. Complications that may require conversion include retrograde intussusception, weight regain, intractable dumping syndrome and nutritional deficiencies; the high cost of obligatory postoperative vitamins is a further reason for conversion in low-income countries. Conversion is technically demanding, carries a relatively higher rate of postoperative complications, and data on its outcomes are limited.
Design: Prospective, single-arm interventional study.
Preoperative assessment: Patients attending the bariatric outpatient clinic who meet the eligibility criteria are enrolled after patient education. History, anthropometric measures, chronic diseases and previous surgeries are recorded. Routine preoperative laboratory tests and imaging are performed, together with a preoperative 3D CT gastric volumetry.
Surgical technique: After pneumoperitoneum and laparoscopic port placement, the previous gastrojejunostomy is closed with an endostapler applied across the anastomosis and fired on the jejunal side. The end of the gastric pouch is then anastomosed to the remnant stomach with an endostapler. A 36 Fr orogastric tube is passed through the anastomosis as a guide, and a sleeve gastrectomy is performed by resecting the stomach along the greater curvature with endostaplers. An intraoperative methylene blue leak test is performed, hemostasis along the staple line is confirmed, and all ports are closed.
Postoperative care and follow-up: Patients stay in hospital for about 24 hours for monitoring of vital signs and the feeding regimen. Nutritional laboratory parameters (hemoglobin, ferritin, vitamin D, zinc, magnesium, serum albumin and calcium), quality of life (Bariatric Quality of Life Index) and GERD symptoms (GERD-HRQL questionnaire) are assessed at 3 and 6 months after surgery. Body weight is recorded monthly to assess weight regain.
Sample size: Calculated with the ClinCalc sample size calculator (alpha 0.05, power 0.80) as 11 patients, including 10% to cover loss to follow-up. A convenience sample of eligible patients is enrolled until this number is reached.
Statistical analysis: SPSS version 21. Categorical data as number and percentage; quantitative data as mean and standard deviation or median and interquartile range. Chi-square, Student t and Mann-Whitney tests, with correlation and regression analysis. Significance at p of 0.05 or less.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Kasr Alaini Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 70 years
- Adult patients with a previous gastric bypass undergoing single-stage laparoscopic stapled conversion of gastric bypass to sleeve gastrectomy
Exclusion Criteria:
- Reversal of gastric bypass to normal anatomy
- Uncontrolled systemic disease
- Active psychological disorder
- Intraoperative technical difficulties preventing conversion of gastric bypass to sleeve gastrectomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Conversion to sleeve gastrectomy
Adults with a previous gastric bypass (RYGB or OAGB) undergoing single-stage laparoscopic stapled conversion to sleeve gastrectomy. |
Stapled closure of the previous gastrojejunostomy on the jejunal side, stapled anastomosis of the gastric pouch to the remnant stomach, then sleeve gastrectomy along the greater curvature over a 36 Fr orogastric tube, with an intraoperative methylene blue leak test. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative leak
Time Frame: From surgery up to 6 months after surgery
|
Number of participants with a staple-line or anastomotic leak after single-stage stapled conversion of gastric bypass to sleeve gastrectomy. |
From surgery up to 6 months after surgery
|
|
Change in nutritional status
Time Frame: Preoperatively, and at 3 and 6 months after surgery
|
Nutritional status assessed with laboratory parameters: hemoglobin, serum ferritin, vitamin D, zinc, magnesium, serum albumin and calcium. |
Preoperatively, and at 3 and 6 months after surgery
|
|
Weight regain
Time Frame: Monthly from surgery up to 6 months after surgery
|
Body weight (kg) recorded monthly after conversion to assess weight regain. |
Monthly from surgery up to 6 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life (Bariatric Quality of Life Index)
Time Frame: 3 and 6 months after surgery
|
Quality of life assessed with the Bariatric Quality of Life (BQL) Index. |
3 and 6 months after surgery
|
|
GERD symptoms (GERD-Health Related Quality of Life questionnaire)
Time Frame: 3 and 6 months after surgery
|
Gastroesophageal reflux symptoms assessed with the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire. |
3 and 6 months after surgery
|
|
Other postoperative complications
Time Frame: From surgery up to 6 months after surgery
|
Number of participants with postoperative complications other than leak, including bleeding and stricture. |
From surgery up to 6 months after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ahmed Mohamed Abdelsalam, MD, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Postoperative Complications
- Pathologic Processes
- Nutrition Disorders
- Overnutrition
- Body Weight
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Postgastrectomy Syndromes
- Obesity
- Dumping Syndrome
Other Study ID Numbers
- N-8-2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.